News & Updates

Febuxostat does not increase risks of CVD events, death

28 Jul 2021

Use of febuxostat is safe and does not lead to a heightened risk of all-cause mortality, death from cardiovascular events (CVD), or CVD events, reports a recent study, adding that the medication is safe for the treatment of gout.

Febuxostat does not increase risks of CVD events, death

28 Jul 2021

Intensified CMV prophylaxis does not reduce infection incidence in kidney recipients

28 Jul 2021 by

Strengthening cytomegalovirus (CMV) prophylaxis with exclusive use of valganciclovir and by extending the course results in longer time to first CMV infection but does not lower the incidence of the disease at 24 months, a Singapore study has shown. Valacyclovir appears to be a good substitute for valganciclovir, especially in resource-limited settings or in situations when the latter cannot be tolerated.

Intensified CMV prophylaxis does not reduce infection incidence in kidney recipients

28 Jul 2021

Voxelotor improves Hb levels, haemolysis markers in younger children with SCD

28 Jul 2021 by

The use of voxelotor weight-based dosing equivalent to 1,500 mg appears to increase haemoglobin (Hb) levels and decrease clinical markers of haemolysis in patients aged 4–11 years with sickle cell disease (SCD), according to a study presented at EHA 2021.

Voxelotor improves Hb levels, haemolysis markers in younger children with SCD

28 Jul 2021

Targeted radioligand therapy ups survival in previously-treated mCRPC

27 Jul 2021 by

Adding the lutetium-labelled PSMA*-617 (177Lu PSMA-617) targeted radioligand therapy to standard of care (SOC) led to significant extension of radiographic progression-free survival (rPFS) and overall survival (OS) compared with SOC alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after treatment with chemotherapy and androgen inhibitors, according to the VISION trial presented at ASCO 2021.

Targeted radioligand therapy ups survival in previously-treated mCRPC

27 Jul 2021

Candesartan may help fight COVID-19

27 Jul 2021 by

Use of the angiotensin receptor blocker (ARB) candesartan in the treatment of COVID-19 appears to shorten hospital stay overall, as well as speed up lung injury resolution and viral clearance for patients without obesity, according to the results of a study from Indonesia.

Candesartan may help fight COVID-19

27 Jul 2021

No excess risk of gastrointestinal malignancies with ranitidine vs other reflux drugs

27 Jul 2021

Use of the histamine-2 receptor antagonist ranitidine does not appear to increase the likelihood of developing gastrointestinal malignancies as compared with omeprazole or famotidine, as shown in a study.

No excess risk of gastrointestinal malignancies with ranitidine vs other reflux drugs

27 Jul 2021

Add-on naltrexone/bupropion helps shed pounds in patients on incretins

27 Jul 2021

The extended-release fixed-dose combination of naltrexone and bupropion (NB) appears to induce weight loss in obese or overweight patients with type 2 diabetes mellitus (T2DM) receiving treatment with dipeptidyl peptidase 4 inhibitors (DPP-4is) or glucagon-like peptide-1 receptor agonists (GLP1-RAs), according to a post-hoc analysis of the LIGHT trial.

Add-on naltrexone/bupropion helps shed pounds in patients on incretins

27 Jul 2021

First dose of ChAdOx1, BNT162b2 vaccines may be protective in LTCF residents after 4 weeks

26 Jul 2021 by

Long-term care facility (LTCF) residents aged ≥65 years appeared to be protected from COVID-19 4–7 weeks after receiving their first dose of the ChAdOx1 nCoV-19 or BNT162b2 vaccine, according to a study presented at ECCMID 2021.

First dose of ChAdOx1, BNT162b2 vaccines may be protective in LTCF residents after 4 weeks

26 Jul 2021

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

26 Jul 2021 by

Patients with psoriasis taking the immunosuppressant methotrexate had low antibody responses to SARS-CoV-2 after receiving the first dose of Pfizer-BioNTech’s BNT162b2 vaccine but had shown T-cell responses, according to a study that was the first to look at T-cell responses in patients taking methotrexate.

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

26 Jul 2021

OTC painkiller use during pregnancy tied to adverse infant outcomes

24 Jul 2021 by

Use of over-the-counter (OTC) painkillers during pregnancy is associated with an increased risk of adverse neonatal outcomes, suggests a large retrospective study presented at ESHRE 2021.

OTC painkiller use during pregnancy tied to adverse infant outcomes

24 Jul 2021

News & Updates

Filter by Specialty:

Specialty:

Febuxostat does not increase risks of CVD events, death

Febuxostat does not increase risks of CVD events, death

Intensified CMV prophylaxis does not reduce infection incidence in kidney recipients

Intensified CMV prophylaxis does not reduce infection incidence in kidney recipients

Voxelotor improves Hb levels, haemolysis markers in younger children with SCD

Voxelotor improves Hb levels, haemolysis markers in younger children with SCD

Targeted radioligand therapy ups survival in previously-treated mCRPC

Targeted radioligand therapy ups survival in previously-treated mCRPC

Candesartan may help fight COVID-19

Candesartan may help fight COVID-19

No excess risk of gastrointestinal malignancies with ranitidine vs other reflux drugs

No excess risk of gastrointestinal malignancies with ranitidine vs other reflux drugs

Add-on naltrexone/bupropion helps shed pounds in patients on incretins

Add-on naltrexone/bupropion helps shed pounds in patients on incretins

First dose of ChAdOx1, BNT162b2 vaccines may be protective in LTCF residents after 4 weeks

First dose of ChAdOx1, BNT162b2 vaccines may be protective in LTCF residents after 4 weeks

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

OTC painkiller use during pregnancy tied to adverse infant outcomes

OTC painkiller use during pregnancy tied to adverse infant outcomes